{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T17:24:42Z","timestamp":1790529882735,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd001021.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T00:00:00Z","timestamp":1522368000000}}],"reference-count":362,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001021.pub3","type":"journal-article","created":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T07:43:32Z","timestamp":1522655012000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis"],"prefix":"10.1002","volume":"2018","author":[{"given":"Sherie","family":"Smith","sequence":"first","affiliation":[{"name":"The University of Nottingham; Division of Child Health, Obstetrics & Gynaecology, School of Medicine; 1701 E Floor East Block Queens Medical Centre Nottingham NG7 2UH UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola J","family":"Rowbotham","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Division of Child Health, Obstetrics & Gynaecology, School of Medicine; 1701 E Floor East Block Queens Medical Centre Nottingham NG7 2UH UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate H","family":"Regan","sequence":"additional","affiliation":[{"name":"NHS Lothian; Royal Infirmary of Edinburgh 51 Little France Crescent Edinburgh UK EH16 4SA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,3,30]]},"reference":[{"key":"10.1002\/14651858.CD001021.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(11)60104-5","article-title":"Lung function improvement with aztreonam 75mg powder and solvent for nebuliser solution (AZLI) in single-arm extension of a randomized trial of inhaled anti-pseudomonal antibiotics in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa infection","volume":"10 Suppl 1","author":"Assael","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0002|cit2","first-page":"312","article-title":"Lung function improvement with aztreonam for inhalation solution (AZLI) in the single-arm extension of a randomized trials of inhaled anti-pseudomonal antibiotics in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa infection","volume":"46 Suppl 34","author":"Assael","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD001021.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jcf.2012.07.006","article-title":"Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial","volume":"12","author":"Assael","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD001021.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"130-40. Online","DOI":"10.1016\/j.jcf.2012.07.006","article-title":"Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial","volume":"12","author":"Assael","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD001021.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"130-40. Online","DOI":"10.1016\/j.jcf.2012.07.006","article-title":"Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial","volume":"12","author":"Assael","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD001021.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"130-40. Online","DOI":"10.1016\/j.jcf.2012.07.006","article-title":"Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial","volume":"12","author":"Assael","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD001021.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"130-40. Online","DOI":"10.1016\/j.jcf.2012.07.006","article-title":"Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial","volume":"12","author":"Assael","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S1569-1993(16)30235-1","article-title":"Post-hoc review of outcomes in patients switching from tobramycin for nebulization solution (TNS) to aztreonam lysine for inhalation (AZLI)","volume":"15 Suppl 1","author":"Fayon","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD001021.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1513\/AnnalsATS.201310-352OC","article-title":"Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis","volume":"11","author":"Nick","year":"2014","journal-title":"Annals of the American Thoracic Society"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0010|cit10","first-page":"327","article-title":"Aztreonam for inhalation solution (AZLI) vs. tobramycin inhalation solution (TIS), a 6-month comparative trial in cystic fibrosis patients with pseudomonas aeruginosa","volume":"45 Suppl 33","author":"Oermann","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0011|cit11","first-page":"289","article-title":"Change in FEV1% predicted in response to aztreonam for inhalation solution (AZLI) vs. tobramycin inhalation solution (TIS) in an active comparator study: responder analyses","volume":"46 Suppl 34","author":"Oermann","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1569-1993(11)60124-0","article-title":"In vitro susceptibility of pseudomonas aeruginosa (PA) does not predict clinical response to aztreonam 75mg powder and solvent for nebuliser solution (AZLI): a responder analysis in subjects with cystic fibrosis","volume":"10 Suppl 1","author":"Pressler","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Meeting abstrac","key":"10.1002\/14651858.CD001021.pub3-BIB0013|cit13","article-title":"An economic evaluation of aztreonam lysine for inhalation and tobramycin for inhalation, in an intermittent aerosolised antibiotic regime, among cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa infection","volume":"185","author":"Schechter","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S1569-1993(14)60048-5","article-title":"Once-daily liposomal amikacin for inhalation is non-inferior to twice-daily tobramycin inhalation solution in improving pulmonary function in cystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa","volume":"13 Suppl 2","author":"Bilton","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD001021.pub3-BIB0015|cit15","article-title":"Interim analysis of a long-term, open-label safety, tolerability, and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic infection due to pseudomonas aeruginosa","volume":"189","author":"Bilton","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0016|cit16","first-page":"290","article-title":"Phase 3 efficacy and safety data from randomized, multicenter study of liposomal amikacin for inhalation (Arikace) compared with TOBI\u00ae in cystic fibrosis patients with chronic infection due to pseudomonas aeruginosa","volume":"48 Suppl 36","author":"Bilton","year":"2013","journal-title":"Pediatric Pulmonology"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD001021.pub3-BIB0017|cit17","article-title":"Clinical benefit of liposomal amikacin for inhalation as assessed by the cystic fibrosis questionnaire-revised","volume":"189","author":"Quittner","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00148581-200709001-00004","article-title":"A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study","volume":"9 Suppl 1","author":"Chuchalin","year":"2007","journal-title":"Paediatric Drugs"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0019|cit19","first-page":"619s","article-title":"Long-term administration of aerosolised tobramycin in patients with cystic fibrosis","volume":"26 Suppl 49","author":"Chuchalin","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S1569-1993(06)80165-7","article-title":"Long-term administration of nebulised tobramycin in patients with cystic fibrosis","volume":"5 Suppl","author":"Chuchalin","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0021|cit21","unstructured":"Day AJ Williams J McKeown C Bruton A Weller PH Evaluation of inhaled colomycin in children with cystic fibrosis 10th International Cystic Fibrosis Congress; 1988 March 5-10; Sydney 1988 106"},{"issue":"5","key":"10.1002\/14651858.CD001021.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jcf.2016.01.005","article-title":"Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"15","author":"Elborn","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1569-1993(14)60050-3","article-title":"Prolonged improvement in lung function and quality of life in cystic fibrosis: a 24-week extension study of levofloxacin nebulization solution (APT-1026) versus tobramycin nebulization solution in stable CF patients with chronic pseudomonas aeruginosa infection","volume":"13 Suppl 2","author":"Elborn","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S1569-1993(13)60108-3","article-title":"Phase 3 trial of inhaled levofloxacin (Aeruquin\u00e2\u2122, MP-376, APT-1026) vs. tobramycin inhalation solution (TIS) in intensively treated CF patients over 6 months","volume":"12 Suppl 1","author":"Elborn","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD001021.pub3-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jcf.2014.12.013","article-title":"A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients","volume":"14","author":"Elborn","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0026|cit26","first-page":"507-14. Online","article-title":"A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients","volume":"14","author":"Elborn","year":"2015","journal-title":"Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/S1569-1993(16)30277-6","article-title":"Microbiologic changes observed over 6 months in a randomized, open-label comparison of inhaled levofloxacin and inhaled tobramycin in persons with cystic fibrosis and chronic P. aeruginosa (Pa) airway infection","volume":"15","author":"Devanter","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6","key":"10.1002\/14651858.CD001021.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jcf.2016.05.001","article-title":"Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis","volume":"15","author":"Flume","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0029|cit29","first-page":"352","article-title":"Aztreonam for inhalation solution (AZLI) and tobramycin inhalation solution (TIS) continuous alternating therapy (CAT) for cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection: a randomized, double-blind, placebo-controlled trial","volume":"50 Suppl 41","author":"Flume","year":"2015","journal-title":"Pediatric Pulmonology"},{"issue":"8256","key":"10.1002\/14651858.CD001021.pub3-BIB0030|cit30","first-page":"1127","article-title":"Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis","volume":"2","author":"Hodson","year":"1981","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD001021.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/jac\/19.6.831","article-title":"Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection","volume":"19","author":"Jensen","year":"1987","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S1569-1993(14)60179-X","article-title":"Tobramycin powder for inhalation is effective in advanced stage CF lung disease: the EAGER trial","volume":"13 Suppl 2","author":"Chiron","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(10)60084-7","article-title":"Treatment convenience and satisfaction of tobramycin inhalation powder (TIPTM) versus TOBI\u00ae in cystic fibrosis (CF) patients","volume":"9 Suppl 1","author":"Geller","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1569-1993(11)60100-8","article-title":"Microbiological and clinical response to tobramycin inhalation powder (TIPTM) in cystic fibrosis patients with chronic Pseudomonas aeruginosa (Pa) infection","volume":"10 Suppl 1","author":"Geller","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD001021.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"388","DOI":"10.4187\/respcare.02264","article-title":"Tobramycin inhalation powder in cystic fibrosis patients: response by age group","volume":"59","author":"Geller","year":"2014","journal-title":"Respiratory Care"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(10)60083-5","article-title":"Safety and efficacy of tobramycin inhalation powder (TIP) in treating CF patients infected with Pseudomonas aeruginosa (Pa)","volume":"9 Suppl 1","author":"Konstan","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0037|cit37","first-page":"303","article-title":"Tobramycin inhalation powder (TIP) versus tobramycin inhalation solution (TOBI\u00ae): the EAGER trial","volume":"45 Suppl 33","author":"Konstan","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD001021.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","article-title":"Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial","volume":"10","author":"Konstan","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0039|cit39","first-page":"344","article-title":"Safety of inhaled tobramycin in patients with cystic fibrosis","volume":"46 Suppl 34","author":"McColley","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0040|cit40","first-page":"283","article-title":"Reduced administration time for inhaled tobramycin in cystic fibrosis patients: results from the EAGER trial","volume":"48 Suppl 36","author":"Nasr","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/S1569-1993(11)60336-6","article-title":"Association of treatment satisfaction and compliance of cystic fibrosis (CF) patients using inhaled tobramycin treatment in the EAGER study","volume":"10 Suppl 1","author":"Regnault","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S1569-1993(11)60345-7","article-title":"Validation of the treatment satisfaction questionnaire for medication (TSQM) in cystic fibrosis (CF)","volume":"10 Suppl 1","author":"Regnault","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6","key":"10.1002\/14651858.CD001021.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jcf.2012.04.007","article-title":"Validation of the treatment satisfaction questionnaire for medication in patients with cystic fibrosis","volume":"11","author":"Regnault","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD001021.pub3-BIB0044|cit44","first-page":"43","article-title":"Nebulized gentamicin in children and adolescents with cystic fibrosis","volume":"20","author":"Kun","year":"1984","journal-title":"Australian Paediatric Journal"},{"issue":"1","key":"10.1002\/14651858.CD001021.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ppul.1950070110","article-title":"Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with pseudomonas aeruginosa","volume":"7","author":"MacLusky","year":"1989","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0046|cit46","first-page":"296","article-title":"Reduction of pulmonary hospitalizations during a randomized, controlled, open-label study of tobramycin solution for inhalation in young CF patients with mild lung disease","volume":"Suppl 25","author":"Anbar","year":"2003","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0047|cit47","first-page":"S22","article-title":"Reduction in pulmonary hospitalizations during a randomized, controlled, open-label study of tobramycin solution for inhalation in young CF patients with mild lung disease","volume":"2 Suppl 1","author":"Colin","year":"2003","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD001021.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ppul.20097","article-title":"Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease","volume":"38","author":"Murphy","year":"2004","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0049|cit49","unstructured":"Nathanson I Cropp GJA Li P Neter P Effectiveness of aerosolized gentamicin in cystic fibrosis (CF) Cystic Fibrosis Club Abstracts; 1985 1985 145"},{"issue":"5","key":"10.1002\/14651858.CD001021.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1155\/2008\/202464","article-title":"A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients","volume":"15","author":"Nikolaizik","year":"2008","journal-title":"Canadian Respiratory Journal"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0051|cit51","first-page":"620s","article-title":"Comparison of tobramycin 80 mg (IV- Preparation) and 300 mg solution for inhalation in cystic fibrosis patients","volume":"26 Suppl 49","author":"Nikolaizik","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0052|cit52","first-page":"S53","article-title":"Comparison of tobramycin 80 mg (IV-preparation) and 300 mg solution inhaled twice daily for chronic P aeruginosa infection","volume":"4 Suppl","author":"Nikolaizik","year":"2005","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0053|cit53","first-page":"273","article-title":"Economic analysis of hospitalization and home IV anti-pseudomonal antibiotic use in CF patients on tobramycin solution for inhalation (TOBI)","volume":"Suppl 17","author":"Birnbaum","year":"1998","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1016\/S1569-1993(02)00003-6","article-title":"The long-term use of inhaled tobramycin in patients with cystic fibrosis","volume":"1 Suppl 2","author":"Bowman","year":"2002","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD001021.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1086\/314727","article-title":"Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis","volume":"179","author":"Burns","year":"1999","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0056|cit56","unstructured":"Casey S Ramsey B Borowitz D Nutritional benefits of chronic intermittent Pseudomonas aeruginosa suppression with tobramycin solution for inhalation in adolescents 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden 2000 172"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0057|cit57","first-page":"339","article-title":"Mortality rates during two years of treatment with intermittent inhaled tobramycin (TOBI) in CF","volume":"Suppl 19","author":"Enger","year":"1999","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0058|cit58","unstructured":"Fiel S Van Devanter DR Yu X Effect of tobramycin solution for inhalation on pulmonary function decline rates in exacerbating and stable CF patients 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna 2001 P195"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0059|cit59","first-page":"1545","article-title":"Long term effect of tobramycin solution for inhalation on reduction of hospitalization of CF patients","volume":"16 Suppl 31","author":"Fiel","year":"2000","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD001021.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1378\/chest.122.1.219","article-title":"Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis","volume":"122","author":"Geller","year":"2002","journal-title":"Chest"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0061|cit61","first-page":"283","article-title":"Epidemiology of Stenotrophomonas maltophilia culture in cystic fibrosis (CF) patients during the tobramycin solution for inhalation (TOBI) study","volume":"Suppl 20","author":"Graff","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD001021.pub3-BIB0062|cit62","first-page":"130","article-title":"Intermitent administration of inhaled tobramycin in patients with cystic fibrosis","volume":"135","author":"Hazinski","year":"1999","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S0300-2977(99)90288-7","article-title":"Who benefits more? An age-stratified analysis of lung function and weight gain in CF patients using inhaled tobramycin","volume":"54 Suppl","author":"Klystra","year":"1999","journal-title":"Netherlands Journal of Medicine"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0064|cit64","first-page":"305","article-title":"Peripheral white blood cell count as a surrogate marker for progression of lung disease in cystic fibrosis","volume":"Suppl 22","author":"Konstan","year":"2001","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD001021.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0149-2918(00)87985-0","article-title":"Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis","volume":"22","author":"LeLorier","year":"2000","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"118S","DOI":"10.1378\/chest.120.3_suppl.118S","article-title":"Microbiological and immunologic considerations with aerosolized drug delivery","volume":"120 Suppl 3","author":"LiPuma","year":"2001","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD001021.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1086\/315312","article-title":"Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment","volume":"181","author":"MacLeod","year":"2000","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0068|cit68","first-page":"243","article-title":"Who benefits more? An analysis of FEV1 and weight in adolescents (age 13 - <18) CF patients using inhaled tobramycin (TOBI)","volume":"Suppl 19","author":"Moss","year":"1999","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"107S","DOI":"10.1378\/chest.120.3_suppl.107S","article-title":"Administration of aerosolized antibiotics in cystic fibrosis patients","volume":"120 Suppl 3","author":"Moss","year":"2001","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD001021.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1378\/chest.121.1.55","article-title":"Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis","volume":"121","author":"Moss","year":"2002","journal-title":"Chest"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0071|cit71","first-page":"243","article-title":"Safety and effectiveness of 2 years of treatment with intermittent inhaled tobramycin in CF patients","volume":"Suppl 19","author":"Nickerson","year":"1999","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0072|cit72","first-page":"273","article-title":"Seasonality of hospitalisations for pulmonary exacerbations and lower respiratory tract infections in phase III tobramycin solution for inhalation trials","volume":"4 Suppl 17","author":"Otto","year":"1998","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/S0300-2977(99)90290-5","article-title":"Treatment for exacerbation only does not arrest progressive lung function decline in CF","volume":"54 Suppl","author":"Quan","year":"1999","journal-title":"Netherlands Journal of Medicine"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0074|cit74","unstructured":"Quittner A Gordon D Yu X Convergence of quality of life assessments and clinical outcomes in patients enrolled in the tobramycin solution for inhalation (TSI) trials 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna 2001 P326"},{"issue":"4","key":"10.1002\/14651858.CD001021.pub3-BIB0076|cit75","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ppul.10074","article-title":"Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection","volume":"33","author":"Quittner","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0075|cit76","first-page":"349","article-title":"Longitudinal changes in global ratings of quality of life for patients in the tobramycin solution for inhalation (TSI) trials","volume":"Suppl 22","author":"Quittner","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0077|cit77","first-page":"137","article-title":"Safety and efficacy of tobramycin solution for inhalation in patients with cystic fibrosis: the results of two phase III placebo controlled clinical trial","volume":"Suppl 14","author":"Ramsey","year":"1997","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0078|cit78","unstructured":"Ramsey BW Bowman MC Montgomery AB Smith AR TOBI Study Group Design of phase 3 aerosolized tobramycin studies for chronic intermittent therapy 21st European Cystic Fibrosis Conference; 1997 Jun 1-6; Davos 1997 144"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0079|cit79","unstructured":"Ramsey BW Bowman MC Vasiljev-K M Smith AR TOBI Study Group Results of Phase 3 aerosolized tobramycin studies for chronic intermittent therapy 21st European Cystic Fibrosis Conference; 1997 Jun 1-6; Davos 1997 144"},{"issue":"1","key":"10.1002\/14651858.CD001021.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis","volume":"340","author":"Ramsey","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001021.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1067\/mpd.2001.117288","article-title":"Defining a pulmonary exacerbation in cystic fibrosis","volume":"139","author":"Rosenfeld","year":"2001","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0082|cit82","first-page":"291","article-title":"Nebulised high dose tobramycin (TOBI) in adolescents with cystic fibrosis","volume":"Suppl 22","author":"Taylor","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0083|cit83","first-page":"298","article-title":"Effect of tobramycin solution for inhalation (TOBI) on long term rates of lung function decline in Pseudomonas aeruginosa-infected cystic fibrosis (CF) patients with mild to moderate lung disease","volume":"Suppl 20","author":"Devanter","year":"2000","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0084|cit84","unstructured":"Van Devanter DR Yu X Konstan MW Effect of tobramycin solution for inhalation on circulating white blood cell counts in exacerbating and stable CF patients 24th European Cystic Fibrosis Conference; 2001 Jun 6-9; Vienna 2001 P172"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S1569-1993(12)60038-1","article-title":"A randomised, open label phase 3 study to evaluate the efficacy and safety of a dry powder formulation of inhaled colistimethate sodium (Colobreanthe\u00ae) verus tobramycin nebuliser solution (TNS) in cystic fibrosis subjects with chronic Pseudomonas aeruginosa lung infection","volume":"11 Suppl 1","author":"Goldman","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0086|cit86","first-page":"331","article-title":"Lack of emergence of antimicrobial resistance of Pseudomonas aeruginosa after six months inhalation of dry powder colistimethate","volume":"43 Suppl 31","author":"Goldman","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0087|cit87","first-page":"353","article-title":"A randomised, open label phase 3 study to evaluate the efficacy and safety of a dry powder formulation of colistimethate sodium (Colobreanthe\u00ae) verus tobramycin nebuliser solution (TNS) in cystic fibrosis subjects with chronic Pseudomonas aeruginosa lung infection","volume":"47 Suppl 35","author":"Goldman","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0088|cit88","first-page":"347","article-title":"Does persistence with inhaled dry powder antibiotic treatment improve tolerability?","volume":"48 Suppl 36","author":"Goldman","year":"2013","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD001021.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"344-350. Online","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD001021.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1569-1993(15)30295-2","article-title":"Efficacy and safety of colistimethate sodium in a paediatric population: results from the FREEDOM trial","volume":"14 Suppl 1","author":"Schuster","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD001021.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0007-0971(87)90161-6","article-title":"Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa","volume":"81","author":"Stead","year":"1987","journal-title":"British Journal of Diseases of the Chest"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0093|cit93","unstructured":"Stead RJ Hodson ME Batten JC Nebulised ceftazidime compared with gentamicin and carbenicillin in adults with cystic fibrosis infected with Pseudomonas aeruginosa 13th Annual Meeting of the European Working Group for Cystic Fibrosis; 1985 Nov 3-8; Jerusalem 1985 51"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0094|cit94","first-page":"250","article-title":"Prevention of chronic Pseudomonas aeruginosa infection by early inhalation therapy with tobramycin","volume":"Suppl 10","author":"Ratjen","year":"1994","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/(SICI)1099-0496(199802)25:2<88::AID-PPUL3>3.0.CO;2-J","article-title":"Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis","volume":"25","author":"Wiesemann","year":"1998","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0096|cit96","first-page":"249","article-title":"A randomised cross over trial of TOBI\u00ae vs IV tobramycin in acute pulmonary exacerbations in CF","volume":"38 Suppl 27","author":"Al-Aloul","year":"2004","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0097|cit97","first-page":"ii79","article-title":"Tobramycin nebuliser solution (TOBI): a renal sparing alternative to intravenous (IV) tobramycin in acute pulmonary exacerbations in CF","volume":"59 Suppl II","author":"Al-Aloul","year":"2004","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0098|cit98","first-page":"ii92","article-title":"Tobramycin nebuliser solution in the treatment of cystic fibrosis pulmonary exacerbations: effect on sputum pseudomonas aeruginosa density","volume":"2 Suppl 2","author":"Al-Aloul","year":"2005","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD001021.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/jamp.2013.1055","article-title":"Nebulized tobramycin in the treatment of adult cf pulmonary exacerbations","volume":"27","author":"Al-Aloul","year":"2014","journal-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery"},{"issue":"3","key":"10.1002\/14651858.CD001021.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1378\/chest.122.3.930","article-title":"Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin","volume":"122","author":"Alothman","year":"2002","journal-title":"Chest"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0101|cit101","first-page":"298","article-title":"In cystic fibrosis (CF) patients, does the inhalation of an intravenous tobramycin preparation result in more bronchospasm than a preservative free tobramycin preparation?","volume":"Suppl 20","author":"Alothman","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD001021.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1378\/chest.127.2.522","article-title":"Bronchial constriction and inhaled colistin in cystic fibrosis","volume":"127","author":"Alothman","year":"2005","journal-title":"Chest"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0103|cit103","first-page":"279","article-title":"Impaired lung function influences the serum concentration of inhaled drugs in cystic fibrosis","volume":"Suppl 20","author":"App","year":"2000","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0104|cit104","unstructured":"Huls G App EM Bittner-Dersch Stolz S Lindemann H Impaired lung function influences the serum concentration of inhaled drugs in cystic fibrosis 13th International Cystic Fibrosis Congress; 2000 Jun 4-8; Stockholm 2000 177"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0105|cit105","first-page":"344","article-title":"The effect of once-a day inhaled liposomal ciprofloxacin hydrochloride on sputum bacterial density in cystic fibrosis patients with chronic pulmonary P aeruginosa colonization","volume":"43 Suppl 31","author":"Bruinenberg","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD001021.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/0007-0971(87)90184-7","article-title":"A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the out-patient management of children with cystic fibrosis","volume":"81","author":"Carswell","year":"1987","journal-title":"British Journal of Diseases of the Chest"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0107|cit107","first-page":"537","article-title":"Bronchial response of children with cystic fibrosis to nebulised antibiotics","volume":"20","author":"Chua","year":"1990","journal-title":"Australian and New Zealand Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD001021.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1183\/09031936.93.03101114","article-title":"Bronchial response to nebulised antibiotics in children with cystic fibrosis","volume":"3","author":"Chua","year":"1990","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD001021.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ppul.21376","article-title":"Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis","volume":"46","author":"Coates","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/S1569-1993(09)60261-7","article-title":"Lung delivery of a new tobramycin nebuliser solution (150mg\/1.5ml) by an investigational eFlow\u00ae nebuliser is equivalent to TOBI\u00ae but in a fraction of time","volume":"8 Suppl 2","author":"Denk","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(10)60085-9","article-title":"In-vivo data support equivalent therapeutic efficacy of a new tobramycin inhalation solution (150mg\/1.5ml) administered by the eFlow\u00ae electronic nebuliser compared to TOBI\u00ae in the PARI LC PLUS\u00ae","volume":"9 Suppl 1","author":"Keller","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0112|cit112","article-title":"Comparison of intravenous and inhalation antibiotic therapy in acute pulmonary deterioration in cystic fibrosis","volume":"131","author":"Cooper","year":"1985","journal-title":"American Review of Respiratory Disease"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/S1569-1993(07)60284-7","article-title":"Piloting the use of the cystic fibrosis questionnaire (CFQ) in CF patients changing to dry powder inhaled colistimethate","volume":"6 Suppl 1","author":"Conway","year":"2007","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0114|cit114","first-page":"283","article-title":"A dry powder formulation of colistimethate sodium is safe and well tolerated in adults and children with CF","volume":"38 Suppl 27","author":"Davies","year":"2004","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S1569-1993(07)60127-1","article-title":"FEV1% predicted may not be a simple end point for CF studies","volume":"6 Suppl 1","author":"Goldman","year":"2007","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0116|cit116","unstructured":"Dodd M Maddison J Abbott J Webb AK The effect of the tonicity of nebulised colistin on lung function in adults with cystic fibrosis 18th European Cystic Fibrosis Conference; 1993 May 21-26; Madrid 1993 121"},{"issue":"7","key":"10.1002\/14651858.CD001021.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/thx.52.7.656","article-title":"Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis","volume":"52","author":"Dodd","year":"1997","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0118|cit118","first-page":"515s","article-title":"The effect of the tonicity of nebulised colistin on chest tightness and lung function in adults with cystic fibrosis","volume":"6 Suppl 17","author":"Dodd","year":"1993","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0119|cit119","first-page":"389","article-title":"Is medicine evidence-based when there is discrepancy between patient reported and objective measures of compliance in clinical trials?","volume":"26 Suppl 17","author":"Dodd","year":"1998","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0120|cit120","unstructured":"Cystic Fibrosis Foundation Inhaled ciprofloxacin www.cff.org\/clinicaltrials"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0121|cit121","first-page":"296","article-title":"Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared with placebo in patients with cystic fibrosis- a phase IIB study of ciprofloxacin dry powder for inhalation (DPI)","volume":"46 Suppl 34","author":"Dorkin","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD001021.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"e000100","DOI":"10.1136\/bmjresp-2015-000100","article-title":"Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis","volume":"2","author":"Dorkin","year":"2015","journal-title":"BMJ Open Respiratory Research"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0123|cit123","unstructured":"NCT00645788 Study to evaluate the safety and efficacy of ciprofloxacin (inhaled) in patients with cystic fibrosis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00645788"},{"issue":"9","key":"10.1002\/14651858.CD001021.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection","volume":"68","author":"Clancy","year":"2013","journal-title":"Thorax"},{"issue":"9","key":"10.1002\/14651858.CD001021.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"818-25. Online","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection","volume":"68","author":"Clancy","year":"2013","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0126|cit126","first-page":"299","article-title":"Full analysis of data from two phase II blinded & placebo-controlled studies of nebulized liposomal amikacin for inhalation (ArikaceTM) in the treatment of CF patients with Pseudomonas aeruginosa lung infection","volume":"45 Suppl 33","author":"Clancy","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1569-1993(08)60099-5","article-title":"A randomised placebo-controlled study of nebulized liposomal amikacin (Arikace\u2122) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection","volume":"7 Suppl 2","author":"Dupont","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD001021.pub3-BIB0128|cit128","article-title":"Evaluation of two phase II blinded and placebo-controlled studies of nebulized liposomal amikacin (Arikace\") in the treatment of cystic fibrosis patients with Pseudomonas aeruginosa lung infection","volume":"181","author":"Dupont","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0129|cit129","first-page":"301","article-title":"A randomized placebo-controlled study of nebulized liposomal amikacin (Arikace\u2122) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection","volume":"43 Suppl 31","author":"Dupont","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD001021.pub3-BIB0130|cit130","article-title":"A randomized placebo-controlled study of nebulized liposomal amikacin (Arikace\u2122) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection (protocol TR02-105)","volume":"179","author":"Gupta","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1378\/chest.111.4.955","article-title":"A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems","volume":"111","author":"Eisenberg","year":"1997","journal-title":"Chest"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1569-1993(15)30294-0","article-title":"Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis trials","volume":"14 Suppl 1","author":"Flume","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD001021.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jcf.2015.12.004","article-title":"A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients","volume":"15","author":"Flume","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD001021.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"495-502. Online","DOI":"10.1016\/j.jcf.2015.12.004","article-title":"A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients","volume":"15","author":"Flume","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0135|cit135","unstructured":"NCT01180634 MP-376 (Aeroquin\u2122, levofloxacin for inhalation) in patients with cystic fibrosis clinicaltrials.gov\/show\/NCT01180634"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0136|cit136","first-page":"356","article-title":"How often is pulmonary exacerbation defined by \u22654 Fuchs criteria associated with antibiotic treatment?","volume":"49 Suppl 38","author":"Devanter","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0137|cit137","unstructured":"Franz MN Spohn WA Ronald PM Evaluation of tobramycin aerosol therapy in cystic fibrosis Cystic Fibrosis Club Abstracts; 1985 1985 143"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0138|cit138","first-page":"288","article-title":"Delay of recurrence of Pseudomonas aeruginosa in patients with cystic fibrosis with inhaled colistin and oral ciprofloxacin; a comparison between 3 weeks and 3 months of treatment","volume":"Supp 14","author":"Frederiksen","year":"1997","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0139|cit139","first-page":"334","article-title":"Endpoints for evaluating early anti-pseudomonal treatment: changes in pseudomonas prevalence and in pulmonary function","volume":"Suppl 25","author":"Frederiksen","year":"2003","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0140|cit140","first-page":"344","article-title":"A randomized, double-blind, placebo-controlled study of tobramycin inhalation powder in patients with cystic fibrosis: the edit trial","volume":"46 Suppl 34","author":"Galeva","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"8","key":"10.1002\/14651858.CD001021.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1185\/03007995.2013.805122","article-title":"Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial","volume":"29","author":"Galeva","year":"2013","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S1569-1993(12)60039-3","article-title":"A challenging double-blind, placebo-controlled study of tobramycin inhalation powder in cystic fibrosis: results of the EDIT trial","volume":"11 Suppl 1","author":"Galeva","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0143|cit143","first-page":"344","article-title":"Long-term safety and efficacy of tobramycin inhalation powder in cystic fibrosis patients with P. aeruginosa: the EDIT trials and its two open-label extension studies","volume":"48 Suppl 36","author":"Konstan","year":"2013","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD001021.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ppul.23358","article-title":"One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis","volume":"51","author":"Konstan","year":"2016","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/S1569-1993(12)60237-9","article-title":"Trends in health-related quality of life (HRQoL) in cystic fibrosis with tobramycin inhalation powder: the EDIT trial","volume":"11 Suppl 1","author":"Quittner","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0146|cit146","first-page":"S22","article-title":"Cross-over study of TOBI\u00ae vs. intravenous tobramycin in combination treatment of pulmonary exacerbations in cystic fibrosis patients","volume":"Suppl 1","author":"Geborek","year":"2003","journal-title":"Journal of Cystic Fibrosis"},{"issue":"7","key":"10.1002\/14651858.CD001021.pub3-BIB0147|cit147","article-title":"The effects of doubling concentration of tobramycin solution for inhalation on pharmacokinetics (PK), safety and delivery time in patients with cystic fibrosis (CF)","volume":"169","author":"Geller","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"7","key":"10.1002\/14651858.CD001021.pub3-BIB0148|cit148","article-title":"Serum pharmacokinetics of two preparations of tobramycin solution for inhalation in young cystic fibrosis patients","volume":"169","author":"Rosenfeld","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0149|cit149","first-page":"250","article-title":"A phase 1 study to assess the tolerability of a novel tobramycin powder for inhalation (TPI) formulation in cystic fibrosis subjects","volume":"38 Suppl 27","author":"Geller","year":"2004","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD001021.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ppul.20594","article-title":"Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety","volume":"42","author":"Geller","year":"2007","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0151|cit151","first-page":"250","article-title":"Single dose pharmacokinetics of tobramycin after administration of a novel dry powder formulation (TPI) in subjects with cystic fibrosis (CF)","volume":"38 Suppl 27","author":"Rodriguez","year":"2004","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S1569-1993(10)60088-4","article-title":"Pharmacokinetics (PK) of aerosol MP-376 (Aeroquin; levofloxacin inhalation solution) in CF patients","volume":"9 Suppl 1","author":"Geller","year":"2010","journal-title":"Journal of Cystis Fibrosis"},{"issue":"6","key":"10.1002\/14651858.CD001021.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1128\/AAC.01744-10","article-title":"Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects","volume":"55","author":"Geller","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD001021.pub3-BIB0154|cit154","article-title":"Phase 2b study of inhaled MP-376 (Aeroquin, levofloxacin inhalation solution) in stable cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (PA) lung infection","volume":"181","author":"Conrad","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S1569-1993(10)60087-2","article-title":"Effects of inhaled MP-376 (Aeroquin, levofloxacin inhalation solution) on lung function in stable cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) lung function","volume":"9 Suppl 1","author":"Flume","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1569-1993(15)30294-0","article-title":"Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis trials","volume":"14 Suppl 1","author":"Flume","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(11)60105-7","article-title":"Effects of inhaled MP-376 (AeroquinTM, levofloxacin inhalation solution) on cystic fibrosis patients with both Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) lung infection","volume":"10 Suppl 1","author":"Flume","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0158|cit158","first-page":"301","article-title":"Effects of inhaled MP-376 (Aeroquin, levofloxacin inhalation solution) on the need for other anti-pseudomonal antimicrobials in stable CF patients with chronic Pseudomonas aeruginosa lung infection","volume":"45 Suppl 33","author":"Geller","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"11","key":"10.1002\/14651858.CD001021.pub3-BIB0160|cit159","doi-asserted-by":"crossref","first-page":"1510-6. Online","DOI":"10.1164\/rccm.201008-1293OC","article-title":"Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with pseudomonas aeruginosa","volume":"183","author":"Geller","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"11","key":"10.1002\/14651858.CD001021.pub3-BIB0159|cit160","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1164\/rccm.201008-1293OC","article-title":"Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa","volume":"183","author":"Geller","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0163|cit161","first-page":"300","article-title":"A randomized controlled trial of inhaled tobramycin in young children with cystic fibrosis: eradication of Pseudomonas from the lower airway","volume":"Suppl 24","author":"Gibson","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD001021.pub3-BIB0161|cit162","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1164\/rccm.200208-855OC","article-title":"Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis","volume":"167","author":"Gibson","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD001021.pub3-BIB0162|cit163","doi-asserted-by":"crossref","first-page":"841. Online sup","DOI":"10.1164\/rccm.200208-855OC","article-title":"Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis","volume":"167","author":"Gibson","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0165|cit164","first-page":"106","article-title":"Serum and lower respiratory tract tobramycin concentrations produced by inhaled tobramycin (TOBI) in young children with cystic fibrosis","volume":"Suppl 19","author":"Rosenfeld","year":"1999","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0164|cit165","first-page":"262","article-title":"Serum pharmacokinetics and safety of inhaled tobramycin in very young CF patients","volume":"Suppl 19","author":"Rosenfeld","year":"1999","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0166|cit166","first-page":"253","article-title":"Safety and tolerability of aztreonam for inhalation (AI) in cystic fibrosis patients","volume":"38 Suppl 27","author":"Gibson","year":"2004","journal-title":"Pediatric Pulmonology"},{"issue":"7","key":"10.1002\/14651858.CD001021.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/ppul.20429","article-title":"Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis","volume":"41","author":"Gibson","year":"2006","journal-title":"Pediatric Pulmonology"},{"issue":"9","key":"10.1002\/14651858.CD001021.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection","volume":"68","author":"Clancy","year":"2013","journal-title":"Thorax"},{"issue":"9","key":"10.1002\/14651858.CD001021.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"818-25. Online","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Phase II studies of nebulised Arikace in CF patients with pseudomonas aeruginosa infection","volume":"68","author":"Clancy","year":"2013","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0170|cit170","first-page":"299","article-title":"Full analysis of data from two phase II blinded & placebo-controlled studies of nebulized liposomal amikacin for inhalation (Arikace) in the treatment of CF patients with Pseudomonas aeruginosa lung infection","volume":"45 Suppl 33","author":"Clancy","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD001021.pub3-BIB0171|cit171","article-title":"Evaluation of two phase II blinded and placebo-controlled studies of nebulized liposomal amikacin (Arikace\") in the treatment of cystic fibrosis patients with Pseudomonas aeruginosa lung infection","volume":"181","author":"Dupont","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0172|cit172","first-page":"295","article-title":"A phase 2 blinded and placebo-controlled study of nebulized liposomal amikacin (Arikace\u2122) in the treatment of CF patients with pseudomonas aeruginosa lung infection","volume":"44 Suppl 32","author":"Goss","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0173|cit173","first-page":"315","article-title":"A phase 1 safety, tolerability and pharmacokinetic (PK) study of MP-376 (levofloxacin solution for inhalation) in stable cystic fibrosis (CF) patients","volume":"43 Suppl 31","author":"Geller","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1569-1993(08)60101-0","article-title":"Single-dose pharmacokinetics of aerosol MP-376 (levofloxacin solution for inhalation) in cystic fibrosis patients: PK-PD implications","volume":"7 Suppl 2","author":"Griffith","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S1569-1993(11)60106-9","article-title":"Levofloxacin pharmacokinetics (PK) after administration of MP-376 (levofloxacin inhalation solution; Aeroquin) in children with cystic fibrosis","volume":"10 Suppl 1","author":"Kearns","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD001021.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/17476348.2015.986469","article-title":"Levofloxacin inhalation solution for the treatment of chronic Pseudomonasaeruginosa infection among patients with cystic fibrosis","volume":"9","author":"Stockmann","year":"2015","journal-title":"Expert Review of Respiratory Medicine"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0177|cit177","unstructured":"Gulliver T Wilson S Williams G Harris M Cooper D Nebulized tobramycin (intravenous solution) is tolerated without inducing cough and wheeze in cystic fibrosis patients Thoracic Society of Australia & New Zealand Annual Scientific Meeting; 2003 April 4-9; Adelaide, Australia 2003"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1569-1993(02)00005-X","article-title":"Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis","volume":"1 Suppl 2","author":"Govan","year":"2002","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0182|cit179","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/S1569-1993(02)00004-8","article-title":"New clinical evidence from the European tobramycin trial in cystic fibrosis","volume":"1 Suppl 2","author":"Hodson","year":"2002","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD001021.pub3-BIB0181|cit180","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1183\/09031936.02.00248102","article-title":"A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis","volume":"20","author":"Hodson","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0179|cit181","first-page":"248","article-title":"Randomised UK \/ Eire clinical trial of the efficacy and safety of tobramycin 300 mg\/5 ml nebuliser solution or nebulised colistin in CF patients","volume":"Suppl 20","author":"Hodson","year":"2000","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0180|cit182","unstructured":"Hodson ME Gallagher CG Govan JRW the PL-TNDS-101 Clinical Trial Group Randomised UK\/Eire clinical trial of the efficacy and safety of tobramycin 300 mg\/5 mL nebuliser solution or nebulised colistin 13th International Cystic Fibrosis Congress; 2000 Jun 4-8; Stockholm 2000 145"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0183|cit183","unstructured":"Jenkins SG Kelly WC Mason WG Peele JD Cruse MA Coludro EO Aerosolized amikacin administration to cystic fibrosis patients chronically infected with Pseudomonas aeruginosa Cystic Fibrosis Club Abstracts; 1985 1985 147"},{"issue":"1","key":"10.1002\/14651858.CD001021.pub3-BIB0184|cit184","first-page":"120","article-title":"Efficacy of aerosolized antibiotics combined with intravenous treatment of cystic fibrosis pulmonary exacerbation","volume":"Suppl 2","author":"Knowles","year":"1998","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0185|cit185","article-title":"Tobramycin inhalation powder is effective and safe in the treatment of chronic pulmonary Pseudomonas aeruginosa (Pa) infection in patients with cystic fibrosis","volume":"179","author":"Konstan","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1569-1993(09)60109-0","article-title":"Effective treatment of chronic Pseudomonas aeruginosa (Pa) infection with tobramycin inhalation powder in CF patients","volume":"8 Suppl 2","author":"Konstan","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ppul.21356","article-title":"Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial","volume":"46","author":"Konstan","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0188|cit188","first-page":"344","article-title":"Safety of inhaled tobramycin in patients with cystic fibrosis","volume":"46 Suppl 34","author":"McColley","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0189|cit189","unstructured":"NCT00125346 Tobramycin inhalation powder (TIP) in cystic fibrosis subjects (EVOLVE) clinicaltrials.gov\/ct2\/show\/NCT00125346"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0190|cit190","unstructured":"Ledson MJ Gallagher MJ Cowperthwaite C Robinson M Convery RP Walshaw MJ A randomised double blind placebo controlled crossover trial of nebulised taurolidine in adult CF patients colonised with B cepacia 22nd European CF Conference; 1998 June 13-19; Berlin, Germany 1998 120"},{"issue":"1","key":"10.1002\/14651858.CD001021.pub3-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/08942680252908575","article-title":"A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia","volume":"15","author":"Ledson","year":"2002","journal-title":"Journal of Aerosol Medicine"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00148581-200709001-00003","article-title":"Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa","volume":"9 Suppl 1","author":"Lenoir","year":"2007","journal-title":"Paediatric Drugs"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S1569-1993(06)80166-9","article-title":"Aerosolized tobramycin in the treatment of patients with cystic fibrosis and pseudomonas aeruginosa infection","volume":"5 Suppl","author":"Lenoir","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0194|cit194","first-page":"620s","article-title":"Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection","volume":"26 Suppl 49","author":"Lenoir","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/DDDT.S54064","article-title":"Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study","volume":"8","author":"Mainz","year":"2014","journal-title":"Drug Design, Development and Therapy"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1569-1993(11)60101-X","article-title":"Sinonasal inhalation of tobramycin in cystic fibrosis patients with P. aeruginosa colonization of the upper airways - results of a multicentric placebo-controlled pilot study","volume":"10 Suppl 1","author":"Mainz","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD001021.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.anl.2010.09.001","article-title":"Sinonasal inhalation of dornase alfa in CF: A double-blind placebo-controlled cross-over pilot trial","volume":"38","author":"Mainz","year":"2011","journal-title":"Auris, Nasus, Larynx"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD001021.pub3-BIB0198|cit198","first-page":"A3121","article-title":"Efficacy and safety of two inhaled tobramycin solutions in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection: results from a head to head comparison","volume":"183","author":"Cicirello","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"11","key":"10.1002\/14651858.CD001021.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ppul.22989","article-title":"Long-term efficacy and safety of aerosolized tobramycin 300 mg\/4 ml in cystic fibrosis","volume":"49","author":"Mazurek","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0200|cit200","first-page":"S28","article-title":"Comparison of two inhaled tobramycin solutions in cystic fibrosis patients with chronic pseudomonas aeruginosa infection: results in different age subgroups","volume":"10 Suppl 1","author":"Mazurek","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/S1569-1993(12)60239-2","article-title":"Efficacy on lung function and safety of multiple courses of tobramycin 300mg\/4 ml nebuliser solution (Bramitob) in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection: results from a 48-week extension phase","volume":"11 Suppl 1","author":"Mazurek","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0202|cit202","first-page":"S28","article-title":"Head-to-head comparison of two inhaled tobramycin solutions in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (Pa) infection","volume":"10 Suppl 1","author":"Mazurek","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0203|cit203","first-page":"341","article-title":"Investigation of susceptibility breakpoints for inhaled antibiotic therapies in cystic fibrosis","volume":"45 Suppl 33","author":"McCoy","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S1569-1993(07)60033-2","article-title":"Aztreonam lysine for inhalation (AZLI) for CF patients with P. aeruginosa (PA) infection","volume":"6 Suppl 1","author":"McCoy","year":"2007","journal-title":"Journal of Cystic Fibrosis"},{"issue":"9","key":"10.1002\/14651858.CD001021.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1164\/rccm.200712-1804OC","article-title":"Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis","volume":"178","author":"McCoy","year":"2008","journal-title":"American Journal of Respiratory Critical Care Medicine"},{"issue":"9","key":"10.1002\/14651858.CD001021.pub3-BIB0206|cit206","first-page":"921-8, Online d","article-title":"Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis","volume":"178","author":"McCoy","year":"2008","journal-title":"American Journal of\u00a0 Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S1569-1993(09)60112-0","article-title":"Efficacy of aztreonam lysine for inhalation (AZLI) in patients with cystic fibrosis and drug resistant P. aeruginosa (DRPA)","volume":"8 Suppl 2","author":"McCoy","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0208|cit208","first-page":"351","article-title":"Relevance of established susceptibility breakpoints to clinical efficacy of inhaled antibiotic therapies in cystic fibrosis","volume":"43 Suppl 31","author":"McCoy","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD001021.pub3-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jcf.2016.12.003","article-title":"Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis","volume":"16","author":"Nichols","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"issue":"14","key":"10.1002\/14651858.CD001021.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2165\/10484070-000000000-00000","article-title":"Aztreonam lysine for inhalation solution in cystic fibrosis","volume":"70","author":"Plosker","year":"2010","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0211|cit211","first-page":"S53","article-title":"Intra-pulmonal deposition of two different tobramycin formulations","volume":"4 Suppl 1","author":"Mullinger","year":"2005","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0212|cit212","first-page":"P2403","article-title":"Comparison of high resolution computerized tomography (HRCT) of the chest and pulmonary function testing in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis (CF) patients","volume":"24 Suppl 48","author":"Nasr","year":"2004","journal-title":"European Respiratory Journal"},{"issue":"12","key":"10.1002\/14651858.CD001021.pub3-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ppul.20447","article-title":"High resolution computerized tomography of the chest and pulmonary function testing in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis patients","volume":"41","author":"Nasr","year":"2006","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0214|cit214","first-page":"299","article-title":"Comparison of high resolution computerized tomography (HRCT) of the chest and pulmonary function testing in evaluating of the effect of tobramycin solution for inhalation (TSI) in cystic fibrosis (CF) subjects with mild lung disease","volume":"38 Suppl 27","author":"Nasr","year":"2004","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD001021.pub3-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/ppul.21188","article-title":"The use of high resolution computerized tomography (HRCT) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung disease","volume":"45","author":"Nasr","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0216|cit216","first-page":"366","article-title":"High resolution computerized tomography (HRCT) of the chest vs. pulmonary function testing utility in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis","volume":"43 Suppl 31","author":"Nasr","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/BF01957914","article-title":"Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis","volume":"155","author":"Nikolaizik","year":"1996","journal-title":"European Journal of Pediatrics"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0218|cit218","first-page":"332","article-title":"Comparison of antibiotics for early pseudomonas infection in CF: interim data analysis","volume":"42 Suppl 30","author":"Noah","year":"2007","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD001021.pub3-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ppul.21176","article-title":"Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas","volume":"45","author":"Noah","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD001021.pub3-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0022-3476(82)80726-9","article-title":"Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin","volume":"101","author":"Nolan","year":"1982","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0221|cit221","first-page":"309","article-title":"Antibiotic susceptibility in Pseudomonas aeruginosa (PA) isolates following repeated exposure to aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis","volume":"44 Suppl 32","author":"Oermann","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0222|cit222","first-page":"335","article-title":"Effect of repeated exposure to aztreonam for inhalation solution (AZLI) therapy on cystic fibrosis respiratory pathogens","volume":"44 Suppl 32","author":"Oermann","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0223|cit223","first-page":"S28","article-title":"Effect of multiple courses of aztreonam lysine for inhalation (AZLI) on FEV1 and weight in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): analysis of 18 month data from CP-AI-006","volume":"8 Suppl 2","author":"Oermann","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0224|cit224","first-page":"S28","article-title":"Adherence over multiple courses of Aztreonam for inhalation (AZLI): effect on disease-related end points in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA)","volume":"8 Suppl 2","author":"Oermann","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S1569-1993(06)80167-0","article-title":"Clinical pharmacology study of a new tobramycin solution for nebulisation","volume":"5 Suppl","author":"Poli","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0226|cit226","first-page":"729s","article-title":"Clinical pharmacology study of a new tobramycin solution for nebulisation","volume":"26 Suppl 49","author":"Poli","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/00148581-200709001-00002","article-title":"Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi","volume":"9 Suppl 1","author":"Poli","year":"2007","journal-title":"Paediatric Drugs"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0228|cit228","first-page":"263","article-title":"Effects of gentamicin on ion transport, MRNA and protein CFTR expression in patients with R1162X: a double blind placebo controlled study","volume":"Suppl 24","author":"Pradal","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/S1569-1993(08)60246-5","article-title":"Eradication of recent Pseudomonas aeruginosa isolation: TOBI versus colistin\/ ciprofloxacin","volume":"7 Suppl 2","author":"Proesmans","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0230|cit230","first-page":"321","article-title":"Eradication of recent Pseudomonas aeruginosa isolation: TOBI versus colistin\/ciprofloxacin","volume":"44 Suppl 32","author":"Proesmans","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1569-1993(11)60119-7","article-title":"Eradication of recent pseudomonas aeruginosa infection: TOBI versus Colistineb\u00ae\/ ciprofloxacin","volume":"10 Suppl 1","author":"Proesmans","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD001021.pub3-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2012.06.001","article-title":"Comparison of two treatment regimens for eradication of pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"12","author":"Proesmans","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"61S","DOI":"10.1378\/chest.107.2_Supplement.61S","article-title":"Aerosol delivery of antibiotics to the lower airways of patients with cystic fibrosis","volume":"107 Suppl 2","author":"Fiel","year":"1995","journal-title":"Chest"},{"issue":"24","key":"10.1002\/14651858.CD001021.pub3-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1056\/NEJM199306173282403","article-title":"Efficacy of aerosolized tobramycin in patients with cystic fibrosis","volume":"328","author":"Ramsey","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD001021.pub3-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jcf.2012.08.001","article-title":"Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial","volume":"12","author":"Anstead","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0236|cit236","first-page":"303","article-title":"Pseudomonas aeruginosa serology predicts response to treatment and re-infection in the EPIC clinical study","volume":"46 Suppl 34","author":"Anstead","year":"2001","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD001021.pub3-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jcf.2013.07.006","article-title":"Pulmonary exacerbations in CF patients with early lung disease","volume":"13","author":"Anstead","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0238|cit238","first-page":"183","article-title":"Safety and efficacy of anti-pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study","volume":"44 Suppl 32","author":"Hamblett","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0239|cit239","first-page":"317","article-title":"Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC clinical trial","volume":"47 Suppl 35","author":"Hoffman","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0240|cit240","first-page":"349","article-title":"Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients","volume":"49","author":"Jorth","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0241|cit241","first-page":"304","article-title":"Early evolution of pseudomonas aeruginosa during cystic fibrosis infection","volume":"50 Suppl 41","author":"Jorth","year":"2015","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0242|cit242","first-page":"335","article-title":"Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants & prior antibiotic exposure","volume":"45 Suppl 33","author":"Khan","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD001021.pub3-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/cid\/civ377","article-title":"Impact of sustained eradication of new pseudomonas aeruginosa Infection on long-term outcomes in cystic fibrosis","volume":"61","author":"Mayer-Hamblett","year":"2015","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD001021.pub3-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ppul.21525","article-title":"Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis","volume":"47","author":"Mayer-Hamblett","year":"2012","journal-title":"Pediatric Pulmonology"},{"issue":"10","key":"10.1002\/14651858.CD001021.pub3-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ppul.22693","article-title":"Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis","volume":"48","author":"Mayer-Hamblett","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0246|cit246","first-page":"146","article-title":"TOBI use in infants and children with early Pseudomonas aeruginosa infection - duration of effect and epic update","volume":"40 Suppl 28","author":"Ramsey","year":"2005","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/S1569-1993(10)60210-X","article-title":"Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"9 Suppl 1","author":"Treggiari","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0248|cit248","first-page":"316","article-title":"Early anti-pseudomonal infection in children with CF: study population and conduct of the \"EPIC\" clinical trial","volume":"44 Suppl 32","author":"Treggiari","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"9","key":"10.1002\/14651858.CD001021.pub3-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archpediatrics.2011.136","article-title":"Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"165","author":"Treggiari","year":"2011","journal-title":"Archives of Pediatric & Adolescent Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001021.pub3-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cct.2009.01.003","article-title":"Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study","volume":"30","author":"Treggiari","year":"2009","journal-title":"Contempory Clinical Trials"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0251|cit251","first-page":"318","article-title":"Inhaled tobramycin nebuliser solution for treatment of early Pseudomonas aeruginosa infection: first results from the Elite study","volume":"41 Suppl 29","author":"Ratjen","year":"2006","journal-title":"Pediatric Pulmonlogy"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(06)80085-8","article-title":"Safety of inhaled tobramycin nebuliser solution for treatment of early pseudomonas aeruginosa infection: first results from the ELITE study","volume":"5 Suppl","author":"Ratjen","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0254|cit253","first-page":"319","article-title":"Short and long-term efficacy of inhaled tobramycin in early P. aeruginosa infection: the ELITE study","volume":"43 Suppl 31","author":"Ratjen","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD001021.pub3-BIB0253|cit254","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/thx.2009.121657","article-title":"Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial","volume":"65","author":"Ratjen","year":"2010","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1569-1993(08)60098-3","article-title":"Inhaled tobramycin nebulizer solution for treatment of early Pseudomonas aeruginosa infection; the ELITE study","volume":"7 Suppl 2","author":"Ratjen","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0256|cit256","first-page":"341","article-title":"Investigation of susceptibility breakpoints for inhaled antibiotic therapies in cystic fibrosis","volume":"45 Suppl 33","author":"McCoy","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S1569-1993(09)60112-0","article-title":"Efficacy of aztreonam lysine for inhalation (AZLI) in patients with cystic fibrosis and drug resistant P. aeruginosa (DRPA)","volume":"8 Suppl 2","author":"McCoy","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0258|cit258","first-page":"351","article-title":"Relevance of established susceptibility breakpoints to clinical efficacy of inhaled antibiotic therapies in cystic fibrosis","volume":"43 Suppl 31","author":"McCoy","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"14","key":"10.1002\/14651858.CD001021.pub3-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2165\/10484070-000000000-00000","article-title":"Aztreonam lysine for inhalation solution in cystic fibrosis","volume":"70","author":"Plosker","year":"2010","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0260|cit260","first-page":"299","article-title":"Effects of chronic intermittent aztreonam for inhalation solution (AZLI) on health-related quality of life (HRQOL) in persons with cystic fibrosis (CF) and P. aeruginosa","volume":"46 Suppl 34","author":"Quitnner","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0261|cit261","first-page":"305","article-title":"Effect of a 28-day course of aztreonam for inhalation solution (AZLI) on responses to individual CFQ-R respiratory symptoms score questions among patients with CF","volume":"44 Suppl 32","author":"Quittner","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0262|cit262","first-page":"320","article-title":"Source of improvements in lung function in patients with cystic fibrosis (CF) following treatment with aztreonam lysine for inhalation (AZLI)","volume":"42 Suppl 30","author":"Retsch-Bogart","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0263|cit263","first-page":"320","article-title":"Sustained improvement in pulmonary function following a 28-day course of 75 MG AZLI TID therapy","volume":"43 Suppl 31","author":"Retsch-Bogart","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0264|cit264","first-page":"310","article-title":"Phase 3 trial (AIR-CF 1) measuring improvement in respiratory symptoms in patients with cystic fibrosis (CF) following treatment with aztreonam lysine for inhalation","volume":"42 Suppl 30","author":"Retsch-Bogart","year":"2007","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD001021.pub3-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1378\/chest.08-1421","article-title":"Efficacy and safety of inhaled aztreonam lysing for airway pseudomonas in cystic fibrosis","volume":"135","author":"Retsch-Bogart","year":"2009","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD001021.pub3-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jcf.2011.02.007","article-title":"Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa","volume":"10","author":"Wainwright","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0267|cit267","first-page":"S55","article-title":"Microbiology results from a phase 2 clinical study of aztreonam lysinate for inhalation (AI): a new inhaled antibiotic to treat CF patients with Pseudomonas aeruginosa (PA)","volume":"4 Suppl","author":"Burns","year":"2005","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD001021.pub3-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ppul.20736","article-title":"A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection","volume":"43","author":"Retsch-Bogart","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0269|cit269","unstructured":"Retsch-Bogart GZ Gibson RL AI Phase 2 Study Group A phase 2 study of aztreonam lysinate for inhalation to treat cystic fibrosis patients with Pseudomonas aeruginosa infection American Thoracic Society International Conference; 2005 May 20-25; San Diego, USA 2005 A576"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0270|cit270","first-page":"320","article-title":"Sustained improvement in pulmonary function following a 28-day course of 75 MG AZLI TID therapy","volume":"43 Suppl 31","author":"Retsch-Bogart","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1569-1993(09)60110-7","article-title":"Pharmacokinetics of tobramycin (TOBI\u2122) after 4 and 8 weeks of continuous once daily or twice daily inhalation","volume":"8 Suppl 2","author":"Rietschel","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0272|cit272","first-page":"320","article-title":"Pharmacokinetics of continuous treatment with o.d. or b.i.d inhalation of tobramycin (TOBI\u2122) via Pari EFlow\u2122 Rapid","volume":"45 Suppl 33","author":"Rietschel","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S1569-1993(10)60086-0","article-title":"Pharmacokinetics of continuous treatment with o.d. or b.i.d. inhalation of tobramycin (TOBI\u2122)","volume":"9 Suppl 1","author":"Rietschel","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD001021.pub3-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/jac\/dkv399","article-title":"Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients","volume":"71","author":"Koningsbruggen-Rietschel","year":"2016","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0275|cit275","first-page":"327","article-title":"Does tobramycin accumulate in respiratory secretions with repeated aerosol administration: a pilot study","volume":"41 Suppl 29","author":"Rosenfeld","year":"2006","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD001021.pub3-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/jamp.2011.0942","article-title":"Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin","volume":"26","author":"Ruddy","year":"2013","journal-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jcf.2014.04.006","article-title":"Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS","volume":"13","author":"Sands","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0278|cit278","first-page":"S66","article-title":"A randomised comparison of VANTOBRA and TOBI in cystic fibrosis patients with chronic pseudomonas aeruginosa infection for pharmacokinetic and therapeutic equivalence","volume":"12 Suppl 1","author":"Sands","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0279|cit279","first-page":"P1188","article-title":"Use of an electronic monitoring system to generate objective information on patients' adherence to taking treatments of a novel inhaled tobramycin solution","volume":"42 Suppl 57","author":"Sands","year":"2013","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0280|cit280","first-page":"S66","article-title":"Use of an electronic monitoring system to generate objective information on patients' adherence to taking treatments of a novel tobramycin solution (VANTOBRA)","volume":"12 Suppl 1","author":"Sands","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD001021.pub3-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0022-3476(87)80130-0","article-title":"Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis","volume":"111","author":"Schaad","year":"1987","journal-title":"Journal of Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD001021.pub3-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00006454-199701000-00032","article-title":"Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis","volume":"16","author":"Schaad","year":"1997","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0283|cit283","unstructured":"Shatunov SM Comparative efficacy of different methods of ceftazidime administration in children with cystic fibrosis 11th European Respiratory Society Annual Congress; 2001 Sept 22-26; Berlin 2001 860"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ppul.1950070413","article-title":"Safety of aerosol tobramycin administration for three months to patients with cystic fibrosis","volume":"7","author":"Smith","year":"1989","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0285|cit285","first-page":"302","article-title":"Safety, tolerability and pharmacokinetics of ciprofloxacin dry powder for inhalation in adolescent patients with CF","volume":"44 Suppl 32","author":"Stass","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD001021.pub3-BIB0286|cit286","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1089\/jamp.2013.1056","article-title":"Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study","volume":"28","author":"Stass","year":"2015","journal-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0287|cit287","first-page":"300","article-title":"Safety and pharmacokinetics of inhaled dry powder ciprofloxacin after single and multiple inhalations in patients with cystic fibrosis","volume":"43 Suppl 31","author":"Stass","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"10","key":"10.1002\/14651858.CD001021.pub3-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.clinthera.2013.08.003","article-title":"Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study","volume":"35","author":"Stass","year":"2013","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3109\/00365528809090221","article-title":"Long-term tobramycin aerosol therapy of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis","volume":"23 Suppl 143","author":"Gappa","year":"1988","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.1950060207","article-title":"Long-term tobramycin aerosol therapy in cystic fibrosis","volume":"6","author":"Steinkamp","year":"1989","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0291|cit291","first-page":"300","article-title":"Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic Pseudomonas aeruginosa infection","volume":"42 Suppl 30","author":"Steinkamp","year":"2007","journal-title":"Pediatric Pulmology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S1569-1993(06)80098-6","article-title":"Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa","volume":"5 Suppl","author":"Steinkamp","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD001021.pub3-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00006454-198305000-00007","article-title":"Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis","volume":"2","author":"Stephens","year":"1983","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0294|cit294","unstructured":"Heaf DP Tyson S Dinwiddie R Matthew D A comparison of inhaled therapies in children with cystic fibrosis 9th International Cystic Fibrosis Congress; 1984 June 9-15; Brighton, England 1984 274"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0295|cit295","unstructured":"Stroobant J Heaf DP Tyson S Matthew DJ Effect of inhaled azlocillin, mistabron and combination therapy in children with cystic fibrosis 13th Annual Meeting of European Working Group for Cystic Fibrosis; 1985 Nov 3-8; Jerusalem 1985 47"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1203\/00006450-198510000-00183","article-title":"Effect of inhaled azlocillin, mistabron and combination therapy in children with cystic fibrosis","volume":"19","author":"Stroobant","year":"1985","journal-title":"Pediatric Research"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S1569-1993(09)60148-X","article-title":"Prevention of initial P. aeruginosa infection in children with cystic fibrosis: a multi-centre double-blind randomised controlled trial","volume":"8 Suppl 2","author":"Tramper-Stranders","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"issue":"10","key":"10.1002\/14651858.CD001021.pub3-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1136\/thx.2009.126128","article-title":"Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"65","author":"Tramper-Stranders","year":"2010","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0299|cit299","first-page":"338","article-title":"Fosfomycin\/tobramycin for inhalation (FTI): microbiological results of a phase 2 placebo-controlled trial in patients with cystic fibrosis and pseudomonas aeruginosa","volume":"45 Suppl 33","author":"McColley","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0300|cit300","first-page":"302","article-title":"Fosfomycin\/tobramycin for inhalation FTI): safety results of a phase 2 placebo-controlled trial in patients with cystic fibrosis and pseudomonas aeruginosa","volume":"45 Suppl 33","author":"Trapnell","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD001021.pub3-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1164\/rccm.201105-0924OC","article-title":"Fosfomycin\/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection","volume":"185","author":"Trapnell","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0302|cit302","first-page":"302","article-title":"Fosfomycon\/tobramycin for inhalation (FTI): efficacy results of a phase 2 placebo-controlled trial in patients with cystic fibrosis and pseudomonas aeruginosa","volume":"45 Suppl 33","author":"Trapnell","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"8769","key":"10.1002\/14651858.CD001021.pub3-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0140-6736(91)91446-2","article-title":"Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment","volume":"338","author":"Valerius","year":"1991","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0304|cit304","first-page":"219","article-title":"Prevention of chronic colonization with Pseudomonas aeruginosa in patients with CF by early treatment with ciprofloxacin and colistin aerosol inhalations","volume":"Suppl 5","author":"Valerius","year":"1990","journal-title":"Pediatric Pulmonology"},{"issue":"7","key":"10.1002\/14651858.CD001021.pub3-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/thoraxjnl-2012-202342","article-title":"Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age","volume":"68","author":"Byrnes","year":"2013","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S1569-1993(09)60157-0","article-title":"Interim outcomes of Pseudomonas aeruginosa (Pa) eradication protocol in young children in the Australasian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) Study","volume":"8 Suppl 2","author":"Cheney","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/S1569-1993(10)60452-3","article-title":"Trials, tribulations and triumphs of a cystic fibrosis study - a behind the scenes look at the workings of an international multi-centre study","volume":"9 Suppl 1","author":"Cheney","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD001021.pub3-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jcf.2014.12.007","article-title":"Pseudomonas aeruginosa genotypes acquired by children with cystic fibrosis by age 5-years","volume":"14","author":"Kidd","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD001021.pub3-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jpeds.2014.05.031","article-title":"Costs of bronchoalveolar lavage-directed therapy in the first 5 years of life for children with cystic fibrosis","volume":"165","author":"Moodie","year":"2014","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0310|cit310","first-page":"317","article-title":"Australasian cystic fibrosis BAL study interim analysis","volume":"41 Suppl 29","author":"Wainwright","year":"2006","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0311|cit311","first-page":"300","article-title":"Early infection with pseudomonas aeruginosa can be cleared in young children with cystic fibrosis","volume":"Suppl 24","author":"Wainwright","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"10","key":"10.1002\/14651858.CD001021.pub3-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/ppul.20885","article-title":"Safety of bronchoalveolar lavage in young children with cystic fibrosis","volume":"43","author":"Wainwright","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0313|cit313","first-page":"320","article-title":"Australasian CF bronchoalveolar lavage (ACFBAL) study: P. aeruginosa (PA) genotypes in pre-school CF children","volume":"46 Suppl 34","author":"Wainwright","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD001021.pub3-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"163-171. Online","DOI":"10.1001\/jama.2011.954","article-title":"Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial","volume":"306","author":"Wainwright","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD001021.pub3-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jama.2011.954","article-title":"Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial","volume":"306","author":"Wainwright","year":"2011","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(10)60082-3","article-title":"A double-blind, multinational, randomized, placebo-controlled trial evaluating aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF), mild lung disease and P. aeruginosa","volume":"9 Suppl 1","author":"Wainwright","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jcf.2011.02.007","article-title":"Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa","volume":"10","author":"Wainwright","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0318|cit318","unstructured":"Wall MA Steinbach S McNamara M Terry AB Prophylactic inhaled antibiotics in cystic fibrosis 25th Annual Meeting Cystic Fibrosis Club Abstracts;1984; San Jose 1984 35"},{"issue":"8337","key":"10.1002\/14651858.CD001021.pub3-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S0140-6736(83)92428-5","article-title":"Inhaled antibiotics in cystic fibrosis","volume":"1","author":"Wall","year":"1983","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0320|cit320","unstructured":"Wang CI Roldan MA Aufderheide M Sehgal S The effect of tobramycin aerosol to pulmonary infection from Pseudomonas aeruginosa in patients with cystic fibrosis 25th Annual Meeting Cystic Fibrosis Club Abstracts;1984; San Jose 1984 159"},{"issue":"1","key":"10.1002\/14651858.CD001021.pub3-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jcf.2003.12.005","article-title":"Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study","volume":"3","author":"Westerman","year":"2004","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0322|cit322","first-page":"S55","article-title":"Effect of nebulised colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis","volume":"2 Suppl 1","author":"Westerman","year":"2003","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD001021.pub3-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jcf.2006.10.010","article-title":"Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study","volume":"6","author":"Westerman","year":"2007","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0324|cit324","first-page":"S64","article-title":"Colistin dry powder inhalation in cystic fibrosis: novel Twincer\u00ae inhaler compared to nebulization: a pilot study","volume":"4 Suppl 1","author":"Westerman","year":"2005","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0325|cit325","unstructured":"Yasmin N Laraya-Cuasay LR Mueller S Liberi P Braverman S Capitanio M A critical evaluation of antibiotic aerosol in patients with cystic fibrosis 15th Annual Meeting of Cystic Fibrosis Club; 1974 1974"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0326|cit326","first-page":"359","article-title":"Pulmonary exacerbations and changes in lung function in CF adults with P. aeruginosa treated with inhaled levofloxacin (Quinsair\u00ae) or tobramycin","volume":"51 Suppl 45","author":"Fischer","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S1569-1993(16)30278-8","article-title":"History of pulmonary exacerbations (PEx) as a predictor of response to nebulized levofloxacin compared with nebulized tobramycin","volume":"15 Suppl 1","author":"Flume","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1569-1993(15)30294-0","article-title":"Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis trials","volume":"14 Suppl 1","author":"Flume","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0329|cit329","unstructured":"NCT01270347 Trial of aeroquin versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients clinicaltrials.gov\/ct2\/show\/NCT01270347"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0330|cit330","first-page":"356","article-title":"How often is pulmonary exacerbation defined by \u22654 Fuchs criteria associated with antibiotic treatment?","volume":"49 Suppl 38","author":"Devanter","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/S1569-1993(17)30338-7","article-title":"Combined dry powder tobramycin and nebulized colistin versus colistin inhalation in CF patients - a randomised, open label phase III clinical study","volume":"16 Suppl 1","author":"Herrmann","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/S1569-1993(10)60211-1","article-title":"Efficacy and safety of tobramycin and colistin for inhalation in children with cystic fibrosis from Moscow region","volume":"9 Suppl 1","author":"Nikonova","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 47","key":"10.1002\/14651858.CD001021.pub3-BIB0333|cit333","first-page":"380","article-title":"Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the optimize trial","volume":"52","author":"Ramsey","year":"2017","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0334|cit334","first-page":"273","article-title":"Economic analysis of hospitalization and home IV anti-pseudomonal antibiotic use in CF patients on tobramycin solution for inhalation (TOBI)","volume":"Suppl 17","author":"Birnbaum","year":"1998","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD001021.pub3-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1086\/314727","article-title":"Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis","volume":"179","author":"Burns","year":"1999","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0336|cit336","unstructured":"CF Foundation About Cystic Fibrosis www.cff.org\/What-is-CF\/About-Cystic-Fibrosis\/"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0337|cit337","unstructured":"Cystic Fibrosis Trust Antibiotic treatment for cystic fibrosis. Consensus document; 3rd Edition; 2009 May www.cysticfibrosis.org.uk\/\u02dc\/media\/documents\/the-work-we-do\/care\/consensus-docs-with-new-address\/anitbiotic-treatment.ashx?la=en"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0338|cit338","unstructured":"Cystic Fibrosis Trust UK Cystic Fibrosis Registry 2015 annual data report; 2016 Aug www.cysticfibrosis.org.uk\/\u02dc\/media\/documents\/the-work-we-do\/uk-cf-registry\/full-registry-report-2015.ashx?la=en"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0339|cit339","unstructured":"CF Trust What is cystic fibrosis - how common is cystic fibrosis? www.cysticfibrosis.org.uk\/what-is-cystic-fibrosis\/faqs#How common is cystic fibrosis?"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1183\/09031936.00099506","article-title":"Cystic fibrosis mortality and survival in the UK: 1947 - 2003","volume":"29","author":"Dodge","year":"2007","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD001021.pub3-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analysis involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD001021.pub3-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"10","key":"10.1002\/14651858.CD001021.pub3-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1164\/rccm.200705-664OC","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medication for maintenance of lung health","volume":"176","author":"Flume","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0344|cit344","unstructured":"Great Ormond Street Hospital for Children NHS Trust Handbook for the management of children with cystic fibrosis; 2011 Sep www.gosh.nhs.uk\/file\/745\/download?token=pZK-Gnjs"},{"issue":"7414","key":"10.1002\/14651858.CD001021.pub3-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0346|cit346","unstructured":"Higgins JPT Altman DG editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"4","key":"10.1002\/14651858.CD001021.pub3-BIB0347|cit347","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004197.pub5","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","author":"Langton Hewer","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD001021.pub3-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"17","key":"10.1002\/14651858.CD001021.pub3-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1001\/jama.294.17.2203","article-title":"Randomized trials stopped early for benefit","volume":"294","author":"Montori","year":"2005","journal-title":"JAMA"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD001021.pub3-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"152S","DOI":"10.1378\/chest.88.2_Supplement.152S","article-title":"Aerosol deposition considerations in inhalational therapy","volume":"88","author":"Newman","year":"1985","journal-title":"Chest"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0351|cit351","unstructured":"National Institute for Health and Care Excellence Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis. Technology appraisal guidance TA276; 2013 Mar www.nice.org.uk\/Guidance\/ta276"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0352|cit352","unstructured":"National Institute for Health and Clinical Excellence Cystic fibrosis: diagnosis and management nice.org.uk\/guidance\/ng78 2017"},{"key":"10.1002\/14651858.CD001021.pub3-BIB0353|cit353","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"9098","key":"10.1002\/14651858.CD001021.pub3-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0140-6736(97)09174-5","article-title":"Cystic Fibrosis","volume":"351","author":"Rosenstein","year":"1998","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD001021.pub3-BIB0355|cit355","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008319.pub2","article-title":"Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis","author":"Ryan","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD001021.pub3-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1183\/09031936.95.08091594","article-title":"Inhalation of antibiotics in cystic fibrosis","volume":"8","author":"Touw","year":"1995","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD001021.pub3-BIB0357|cit357","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001506.pub3","article-title":"Nebulised hypertonic saline for cystic fibrosis","author":"Wark","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"(1 suppl)","key":"10.1002\/14651858.CD001021.pub3-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1378\/chest.125.1_suppl.1S","article-title":"Cystic fibrosis adult care: Consensus conference report","volume":"125","author":"Yankaskas","year":"2004","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD001021.pub3-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ppul.23036","article-title":"Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis","volume":"50","author":"Zemanick","year":"2015","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD001021.pub3-BIB0360|cit360","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001021","article-title":"Nebulised anti-pseudomonal antibiotics for cystic fibrosis","author":"Ryan","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD001021.pub3-BIB0361|cit361","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001021","article-title":"Nebulised anti-pseudomonal antibiotics for cystic fibrosis","author":"Ryan","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"Issue 3. Art. N","key":"10.1002\/14651858.CD001021.pub3-BIB0362|cit362","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001021.pub2","article-title":"Inhaled antibiotics for long-term therapy in cystic fibrosis","author":"Ryan","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd001021.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD001021.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T14:06:45Z","timestamp":1719929205000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001021.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,3,30]]},"references-count":362,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001021.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD001021.pub4","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,30]]}}}